The heterogeneity of tumour-associated antigen and neoantigen expression in solid tumours is a key feature in tumour vaccine development. Vaccentis has decided to intensify investments in this high priority research area to strengthen research activities and contribute to pipeline development.
🔜 Vaccentis believes that the use of an autologous tumour lysate technology platform is beneficial as it has the potential to overcome the barrier of heterogeneity of tumour-associated antigen expression in the development of patient-specific solid tumour vaccines.
Reference: Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy - PMC (nih.gov)
